Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Immunotherapy
Immunotherapy
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
April 2019, Vol 10, No 2
San Francisco, CA—Chimeric antigen receptor (CAR) T-cell therapy is associated with unique adverse events that require vigilant monitoring, aggressive care, and specialized management. Marco L. Davila, MD, PhD, Medical Oncologist, Blood and Marrow Transplant and Cellular Immunotherapy Program, Moffitt Cancer Center, Tampa, FL, provided an overview of this topic at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Read Article
Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
April 2019, Vol 10, No 2
San Francisco, CA—Promising markers of response to immune checkpoint inhibition include tumor mutation burden (TMB) and genomic markers that reflect a disruption of the tumor immunity cycle, said Natalie Vokes, MD, MPhil, Medical Oncology Fellow, Dana-Farber Cancer Institute, Boston, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Read Article
Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers
By
Wayne Kuznar
Immunotherapy
,
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
April 2019, Vol 10, No 2
San Francisco, CA—Tumor expression of PD-L1 has consistently predicted response and survival outcomes in non–small-cell lung cancer (NSCLC), whereas the role of PD-L1 in immune cells is unclear, said Edward B. Garon, MD, Director, Thoracic Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Read Article
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
By
Wayne Kuznar
Immunotherapy
,
Leukemia
,
Lymphoma
,
Hematologic Malignancies
,
Personalized Medicine
April 2019, Vol 10, No 2
San Francisco, CA—Many patients with leukemia or lymphoma who receive treatment with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy achieve minimum residual disease (MRD) negativity, and many are in complete remission well beyond 12 months.
Read Article
Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma
By
Phoebe Starr
Immunotherapy
,
Multiple Myeloma
,
Hematologic Malignancies
,
Personalized Medicine
Web Exclusives
A dizzying array of new chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) designed specifically for the treatment of multiple myeloma was presented at the 2018 American Society of Hematology (ASH) annual meeting. BCMA-targeted CAR T-cell therapies are designed to improve T-cell persistence, depth of response, and tolerability. Response rates reported at ASH 2018 range from 70% to 100%, depending on the patient population and the use of previous regimens.
Read Article
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—Although chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable long-lasting remissions in B-cell malignancies, in approximately 60% of the cases, the initial response wanes over time because of “immune exhaustion.”
Read Article
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—Longer-term follow-up of 2 large pivotal clinical trials in B-cell malignancies has demonstrated continuing remissions after chimeric antigen receptor (CAR) T-cell therapy: the ELIANA study in pediatric patients and young adults with relapsed or refractory B-acute lymphoblastic leukemia (B-ALL) and the JULIET study in adult patients with diffuse large B-cell lymphoma (DLBCL). Both updates were presented at a press conference at ASH 2018.
Read Article
Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma
By
Phoebe Starr
Immunotherapy
,
Multiple Myeloma
,
Hematologic Malignancies
,
Personalized Medicine
January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights
San Diego, CA—A dizzying array of new chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) designed specifically for the treatment of multiple myeloma was presented at ASH 2018. BCMA-targeted CAR T-cell therapies are designed to improve T-cell persistence, depth of response, and tolerability. Response rates reported at ASH 2018 range from 70% to 100%, depending on the patient population and the use of previous regimens.
Read Article
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Immunotherapy
,
Multiple Myeloma
,
Hematologic Malignancies
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
CAR T-Cell Therapy Yields Impressive Responses in Aggressive Non-Hodgkin Lymphoma
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Lisocabtagene maraleucel (liso-cel), an investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has induced durable responses in high-risk patients with aggressive relapsed or refractory non-Hodgkin lymphoma (NHL), according to data presented at ASCO 2018.
Read Article
Page 2 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma